FIELD: medicine.SUBSTANCE: invention relates to application of formula (I) compound, for preparation of medication, used for treatment of chronic obstructive pulmonary disease. In compound (I)A represents aryl group, selected from phenyl； B represents aryl group, selected from phenyl or pyridyl； X represents carbon atom or nitrogen atom； R represents substituted or non-substituted groups, selected from heteroaryl groups, including pyridyl, thienyl, furyl, pyrrolyl, pyrazolyl, oxazolyl, thiazolyl, imidazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyrimidinyl and pyrazinyl, and heterocyclic groups, including morpholine, thiomorpholine, piperazine, piperidine, piperidin-4-one, pyrrolidine, pyrrole-2,5-dione, thiazolidine, 1-oxido-thiazolidine and 1,1-dioxido-1,3-thiazolidine； where heterocyclic group is optionally substituted with substituents, independently selected from substituted or non-substituted (C)aryl, -CH-Caryl, -CH-heteroaryl, CO-Caryl, -CO-heteroaryl, -CS-heteroaryl, -CO-C-cycloalkyl, cyano(C)alkyl, -O-methyloxime, -SOCl, formyl, or other substituted or non-substituted heterocyclic group, selected from pyridyl, pyrimidinyl and piperidinyl； where binding of heterocyclic group to pyrimidine ring takes place through carbon or nitrogen atom； and where group R or substituent of heterocyclic group R are optionally substituted. Other substituents are given in invention formula.EFFECT: compounds are suitable for treatment of immunological diseases, inflammation, pain impairment, rheumatoid arthritis； osteoporosis, multiple myeloma, uveitis, acute and chronic myelogenous leukaemia； atherosclerosis, cancer, cachexia and other diseases.15 cl, 15 tbl, 158 exИзобретение относится к новым и известным производным пиримидина, обладающим свойствами ингибитора PDE4, и их применению для лечения заболеваний, опосредованных активностью указанного рецептора. Эти соединения пригодны для лечения иммунологических заболеваний, воспаления, болевого нарушения, ревматоидного артрита； ос
